More interestingly, re‐introducing WT, but not the enzyme‐inactive variant Nedd4l‐C962A, could inhibit AKT phosphorylation in NEDD4L‐depleted breast cancer cells, coupled with decreased CTR1 protein levels (Figure 5c). Here, SLC31A1 is linked to breast carcinoma.